287 related articles for article (PubMed ID: 15764279)
1. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer in men using testosterone supplementation.
Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
[TBL] [Abstract][Full Text] [Related]
4. Prostatic complications of testosterone replacement therapy.
Jackson JA; Waxman J; Spiekerman AM
Arch Intern Med; 1989 Oct; 149(10):2365-6. PubMed ID: 2679476
[TBL] [Abstract][Full Text] [Related]
5. Testosterone therapy in the ageing male: what about the prostate?
Schultheiss D; Machtens S; Jonas U
Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer after exogenous testosterone treatment for impotence.
Loughlin KR; Richie JP
J Urol; 1997 May; 157(5):1845. PubMed ID: 9112543
[No Abstract] [Full Text] [Related]
7. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
8. Monitoring androgen replacement therapy: testosterone and prostate safety.
Morales A
J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
[TBL] [Abstract][Full Text] [Related]
9. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer following testosterone replacement in Klinefelter syndrome.
Bydder SA; Joseph DJ; Weinstein S; Stuckey BG
ANZ J Surg; 2007; 77(1-2):93-4. PubMed ID: 17295832
[TBL] [Abstract][Full Text] [Related]
11. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
12. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
Ebert T; Jockenhövel F; Morales A; Shabsigh R
Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
[TBL] [Abstract][Full Text] [Related]
13. Rapid androgen cycling as treatment for patients with prostate cancer.
Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
15. The effect of androgen supplementation therapy on the prostate.
Kaufman JM
Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
[TBL] [Abstract][Full Text] [Related]
16. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
17. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
Morgunov LIu; Vertkin AL; Pushkar' DIu
Urologiia; 2007; (5):49-51. PubMed ID: 18254226
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer in a hypogonadal male receiving androgen supplementation.
Ferri M; Norman RW
Can J Urol; 2000 Jun; 7(3):1055-6. PubMed ID: 11118282
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
Gould DC; Kirby RS
Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
